Norgine B.V., a leading European specialist pharmaceutical company headquartered in Netherlands, today announced the launch of LYMPHOSEEK® (Tc 99m tilmanocept) in Finland and Sweden.
LYMPHOSEEK is a radiopharmaceutical used for diagnostic purposes by nuclear medicine specialists and surgeons. It is specifically designed for a procedure called sentinel lymph node biopsy (SLNB) and represents a significant alternative to the current method of identifying sentinel lymph nodes in adult patients with breast cancer, melanoma, or localised squamous cell carcinoma of the oral cavity.
LYMPHOSEEK has been specifically designed to target, bind to and be retained in sentinel lymph nodes, the first lymph node (or group of nodes) to which cancer cells are most likely to spread from a primary tumour.
Peter Martin, COO at Norgine commented: “By making LYMPHOSEEK® available to patients through our infrastructure in partnership with surgeons, radiopharmacists, and nuclear medicine specialists, we continue to demonstrate our commitment to improving patients’ quality of life with access to new innovative specialist diagnostic tools and treatments. Norgine wants all eligible patients suffering from oral cancer, breast cancer or melanoma to have their cancers accurately staged using sentinel lymph node biopsy with LYMPHOSEEK®. This will result in a reduction in unnecessary surgical interventions that can optimise use of healthcare resources and improve patients’ outcomes.”
LYMPHOSEEK is already available through Norgine in the Netherlands, UK, Italy and Denmark. Further launches of Norgine infrastructure are expected in 2018.